Novocuff Raises $26 Million in Oversubscribed Series A Funding to Advance Technology Aimed at Reducing Preterm Births

“We are thrilled to have the support of a strong and mission-aligned group of investors as we enter this exciting next phase of clinical development,” said Amelia “Amy” Degenkolb, CEO & Co-founder of Novocuff. “This funding catalyzes our ability to deliver a solution to a healthcare need for women, and their families and healthcare providers.”